The current evidence base primarily from animal studies and limited human trials suggests the following potential applications: Improved sleep quality increased proportion of slow-wave sleep, reduced sleep latency, fewer nocturnal cortisol spikes Cortisol normalisation reduced HPA hyperactivation, particularly relevant in high-stress or metabolically burdened patients Nociceptive effects several studies indicate DSIP modulates pain processing, with implications for patients whose poor sleep is pain-driven (3) Antioxidant activity may reduce oxidative stress markers, which are elevated in both sleep-deprived and insulin-resistant individuals Neuroendocrine support preliminary evidence of effects on LH, FSH, and somatostatin hormones that regulate testosterone, oestrogen, and growth hormone release Potential stress adaptation some data suggest DSIP may reduce the physiological stress response magnitude without blunting alertness It is important to be precise here

Moreover, in a Chinese study, peripheral blood mononuclear cells (PBMC) of AIH-1 patients were found to produce high amounts of IFN upon incubation with peptides spanning the SEPSECS protein, potentially a key antigenic target in this condition [73]
No pharmaceutical companies are going to sign up for that, because even if they make it all the way to approval, why would anyone buy it from them if they can already get it from China? What are the side effects of peptides
[Hyaluronate acid for treatment of chondromalacia patellae: a 52-week follow-up study]